Nvidia and a FTSE 100 fund own a 10% stake in this $8 artificial intelligence (AI) stock

Ben McPoland explores Recursion Pharmaceuticals (NASDAQ:RXRX), an up-and-coming AI firm held by Cathie Wood, Nvidia and one FTSE 100 trust.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What have Nvidia and the FTSE 100 got in common? Well, not much in all fairness. But the leader in artificial intelligence (AI) computing and the Footsie’s Scottish Mortgage Investment Trust do both have investments in Recursion Pharmaceuticals (NASDAQ: RXRX).

Between them, they own around a 10% stake in this little-known AI innovator. Meanwhile, famed growth investor Cathie Wood of Ark Invest is also a big fan. Indeed, Ark is actually Recursion’s largest shareholder.

Here’s what investors need to know about this $8 stock.

Biology meets AI

Founded in 2013, Recursion uses big data and machine learning to target a faster, cheaper and better approach to discover medicines. The firm says it is “decoding biology to industrialise drug discovery“.

It uses both public and its own 23 petabyte dataset (which is massive) to discover new compounds and viable candidates to treat rare diseases and certain cancers.

Because its AI replaces human interpretation and dramatically lowers costs, this means it can pursue minor diseases that have been overlooked in the past because they weren’t commercially viable.

For example, it currently has five treatments in phase 2 clinical trials. But each of those will treat an initial patient population between 50,000 and 730,000. That’s small.

If successful though, it will be the only firm serving these markets. There are potentially dozens of such diseases where it could have no competition.

It also licences its platform to other drugmakers and has partnerships with industry giants Roche and Bayer.

Basically then, the aim here is to dramatically lower the costs and time associated with failed drug candidates.

Co-founder and CEO Chris Gibson said its “failure is happening in the first six hours or the first six weeks of the first six months, as opposed to happening six years down the road in Phase 2 or Phase 3.”

Nvidia partnership

Nvidia’s visionary CEO Jensen Huang recently said: “Where do I think the next amazing revolution is going to come? There’s no question that digital biology is going to be it.”

Huang says AI will move biology from science to engineering. And when that happens it becomes “exponentially improving, it can compound on the benefits of previous years.”

As part of its Nvidia link-up, Recursion will add more than 500 Nvidia H100 GPUs to its BioHive-1 supercomputer. Once complete, the firm reckons this will be the most powerful supercomputer owned by any biopharma company.

Recursion does up to 2.2m experiments every week. I’d imagine this upgraded BioHive-1 will take that to another level.

Reality check time

Now, I do have a very small position in this stock. But it’s just to get some skin in the game.

Today, the firm’s primarily making money through its collaborative agreements with drugmakers ($44m last year). It’s likely years away from any profits but has a $2bn market-cap. So this is a risky stock, for sure.

Meanwhile, it ended 2023 with $392m in cash. That’s enough for now but more may be needed in the next couple of years. That could cause share price volatility.

Still, when Nvidia, Scottish Mortgage, and Wood all invest in a particular AI stock, it’s worth taking note. It could be a massive long-term winner, or not. So a small holding is all I want.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Recursion Pharmaceuticals and Scottish Mortgage Investment Trust Plc. The Motley Fool UK has recommended Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This FTSE AIM travel business could absolutely skyrocket in 2025

FTSE AIM stock Jet2 appears to be a bargain in plain sight. I’m desperately searching for reasons not to buy…

Read more »

Investing Articles

This Bank of England news makes me fear for Lloyds and its share price!

Warnings of weak economic growth, resurgent inflation, and falling interest rates pose a toxic cocktail for Lloyds' share price.

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »

Investing Articles

The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's biggest company…

Read more »